risperidone

Details

Generic Name:

risperidone

Project Status:

Pending

Therapeutic Area:

Schizophrenia, adults

Manufacturer:

Teva Canada Innovation

Call for patient/clinician input open:

August 30, 2023

Brand Name:

TBC

Project Line:

Reimbursement Review

Project Number:

SR0811-000

Call for patient/clinician input closed:

October 24, 2023

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of schizophrenia in adults.

Fee Schedule:

Pending

Indications:

For the treatment of schizophrenia in adults.

Anticipated Date:

October 13, 2023

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : August 30, 2023